Redx Pharma (LSE:REDX) Additional Paid-In Capital : £99.50 Mil(As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Redx Pharma Additional Paid-In Capital?

Redx Pharma's quarterly additional paid-in capital stayed the same from Sep. 2022 (£99.50 Mil) to Mar. 2023 (£99.50 Mil) and stayed the same from Mar. 2023 (£99.50 Mil) to Sep. 2023 (£99.50 Mil).

Redx Pharma's annual additional paid-in capital increased from Sep. 2021 (£66.30 Mil) to Sep. 2022 (£99.50 Mil) but then stayed the same from Sep. 2022 (£99.50 Mil) to Sep. 2023 (£99.50 Mil).

Redx Pharma Additional Paid-In Capital Historical Data

The historical data trend for Redx Pharma's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redx Pharma Additional Paid-In Capital Chart

Redx Pharma Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Additional Paid-In Capital

Get a 7-Day Free Trial

33.26

37.19

66.30

99.50

Redx Pharma Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Additional Paid-In Capital	Get a 7-Day Free Trial															66.30	66.30	99.50	99.50	99.50

Redx Pharma Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Redx Pharma Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Redx Pharma's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Redx Pharma (LSE:REDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Redx Pharma PLC (LSE:REDX) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

Block 33, Mereside, Alderley Park, Macclesfield, GBR, SK10 4TG

Website

https://www.redxpharma.com

Redx Pharma PLC is a United Kingdom-based biotechnology company focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases. Its product pipeline under development includes Porcupine Inhibitor, ROCK2 Selective Inhibitor, GI-targeted ROCK inhibitor, Pan-RAF Inhibitor, and others. The firm operates geographically in UK and Ireland. Revenue is generated from; Scientific programmes and research collaboration, Research collaboration and Research and preclinical development services. Redx is a clinical-stage biotechnology company focused on the discovery & development of novel, small-molecule, targeted medicines for the treatment of cancer and fibrotic disease and the emerging area of cancer-associated fibrosis.

Redx Pharma (LSE:REDX) Headlines

No Headlines